Core Insights - CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting calcium release-activated calcium (CRAC) channels for treating acute and chronic inflammatory and immunologic diseases [1][4] - The company will host a symposium titled "Auxora for the Treatment of AKI" at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting from June 24-26 in Vicenza, Italy [1] Presentation Details - The symposium will feature several oral presentations, including an overview of CRAC channels by Dr. Sudarshan Hebbar, scheduled for June 24, 1:45-2:00 p.m. CEST [2] - Another presentation will discuss the role of IL-17 in the pathophysiology of acute kidney injury (AKI) by Dr. Javier Neyra, set for June 24, 2:00-2:20 p.m. CEST [2] - Dr. Lakhmir Chawla will present on the KOURAGE trial (NCT06374797) on June 24, 2:20-2:35 p.m. CEST [3] Company Overview - CalciMedica's proprietary technology aims to inhibit CRAC channels to modulate immune responses and protect against tissue cell injury, potentially addressing life-threatening inflammatory and immunologic diseases without approved therapies [4] - The lead product candidate, Auxora™, has shown positive clinical results in multiple trials and has been well-tolerated in over 350 critically ill patients [4] - The company is conducting several clinical trials, including a Phase 2b trial (CARPO – NCT04681066) for acute pancreatitis and a Phase 2 trial (CARDEA – NCT04345614) for COVID pneumonia, as well as the ongoing KOURAGE trial for AKI with associated acute hypoxemic respiratory failure [4]
CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting